Evonile Pharma (500672) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
13 Oct, 2026Executive summary
Q1 FY25/26 revenue from operations was INR 875.5 million, while profit for the period rose to INR 276.2 million from INR 257.4 million YoY.
Board approved unaudited results for the quarter ended June 30, 2025; statutory auditors issued a limited review report with no material misstatement identified.
Financial highlights
Revenue from operations INR 875.5 million vs INR 922.9 million YoY; total income INR 981.6 million vs INR 1,027.0 million.
Total expenses INR 609.4 million vs INR 690.2 million YoY; profit before tax INR 372.2 million vs INR 336.8 million.
Profit for the period INR 276.2 million vs INR 257.4 million YoY; total comprehensive income INR 276.2 million vs INR 257.4 million.
Segment performance
Operations comprise a single business segment: Pharmaceuticals Business.
Latest events from Evonile Pharma
- H1 profit rose YoY despite weaker Q2 revenue and a 54.0 million tax-litigation provision.500672
Q2 24/25 - Q1 profit rose to ₹257.4 million as revenue reached ₹922.9 million.500672Q1 24/25
- Q3 revenue grew YoY, while profit declined; 9M net profit edged higher.500672Q3 24/25
- FY25 profit and EPS rose despite lower revenue; INR25/share dividend recommended.500672Q4 24/25
- Q2 profit rose YoY; H1 profit advanced despite lower revenue.500672Q2 25/26
- Q3 revenue and profit fell YoY as Labour Code costs and tax adjustments shaped results.500672Q3 25/26
- FY26 profit declined; a proposed 70.68% stake sale awaits approvals.500672Q4 25/26
- Q1 revenue and profit rose YoY as a proposed 70.68% ownership transfer advanced.500672Q1 26/27